The audit letters arriving in pharmacies this year name the same drug class. OptumRx, CVS Caremark, and Express Scripts have concentrated audit activity on GLP-1 receptor agonists, the semaglutide and tirzepatide products that now dominate pharmacy spend. The reimbursement dollars are large, the documentation requirements are dense, and a flagged GLP-1 file can carry a recoupment demand that reaches every claim in the lookback period.
What the Audits Target
GLP-1 audit requests follow a recognizable pattern. Auditors ask for prior authorization records, prescriber communications, proof of patient counseling, dispensing quantities against days supply, and wholesaler invoices that reconcile purchases to dispensings. Findings tend to cluster in four categories: incomplete prior authorization chains, quantity and refill patterns outside plan limits, inventory shortfalls on invoice reconciliation, and missing clinical documentation for off-label or cash-adjacent dispensing.
How a Small Sample Becomes a Large Demand
The audit rarely stops at the claims named in the notice. PBMs apply extrapolation to project the error rate from a reviewed sample across the full audit period, which is how a finding on a handful of fills becomes a six or seven figure demand. The projection method is also where the defense concentrates: sample composition, error-rate calculation, and the contractual authority for extrapolation are each contestable.
A GLP-1 audit is a documentation contest. The pharmacy that can produce the prior authorization chain and the purchase records wins the claims it can prove.
The Defense File
The strongest position is assembled before the response deadline, not after the findings letter. That means a complete prior authorization record for every flagged fill, wholesaler invoices matched to dispensed quantities, prescriber attestations where records are thin, and a claim-by-claim rebuttal rather than a narrative letter. Where findings survive, the remaining fight is over the projection: challenging the sample and the math routinely reduces demands by an order of magnitude. The response sequence in our guide to responding to a PBM audit letter applies with full force to GLP-1 reviews.
Why Early Legal Counsel Is Critical
The first response to the audit notice shapes everything that follows. Producing more than the notice demands, certifying records that contain gaps, or missing a contractual deadline hands the PBM findings it would not otherwise have. Counsel engaged at the notice stage controls the production, preserves the appeal record, and keeps a recoupment dispute from escalating into a network termination or a fraud referral.
How Health Law Alliance Can Help
Health Law Alliance defends pharmacies nationwide in GLP-1 and other PBM audits, from the first notice through appeal and negotiation. The firm's bench includes attorneys who built and ran PBM audit programs before defending against them. If your pharmacy has received a GLP-1 audit notice, contact us today for a free consultation before the response deadline runs.
